作者
Jonas Hugosson, Monique J Roobol, Marianne Månsson, Teuvo LJ Tammela, Marco Zappa, Vera Nelen, Maciej Kwiatkowski, Marcos Lujan, Sigrid V Carlsson, Kirsi M Talala, Hans Lilja, Louis J Denis, Franz Recker, Alvaro Paez, Donella Puliti, Arnauld Villers, Xavier Rebillard, Tuomas P Kilpeläinen, Ulf H Stenman, Rebecka Arnsrud Godtman, Karin Stinesen Kollberg, Sue M Moss, Paula Kujala, Kimmo Taari, Andreas Huber, Theodorus van Der Kwast, Eveline A Heijnsdijk, Chris Bangma, Harry J De Koning, Fritz H Schröder, Anssi Auvinen
发表日期
2019/7/1
期刊
European urology
卷号
76
期号
1
页码范围
43-51
出版商
Elsevier
简介
Background
The European Randomized study of Screening for Prostate Cancer (ERSPC) has previously demonstrated that prostate-specific antigen (PSA) screening decreases prostate cancer (PCa) mortality.
Objective
To determine whether PSA screening decreases PCa mortality for up to 16 yr and to assess results following adjustment for nonparticipation and the number of screening rounds attended.
Design, setting, and participants
This multicentre population-based randomised screening trial was conducted in eight European countries. Report includes 182 160 men, followed up until 2014 (maximum of 16 yr), with a predefined core age group of 162 389 men (55–69 yr), selected from population registry.
Outcome measurements and statistical analysis
The outcome was PCa mortality, also assessed with adjustment for nonparticipation and the number of screening rounds attended.
Results and limitations
The rate …
学术搜索中的文章
J Hugosson, MJ Roobol, M Månsson, TLJ Tammela… - European urology, 2019